PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för aclacinomycin A. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

20 hits

Bibliografisk träff 2013-05-21

TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Jain M, Zhang L, He M, Zhang YQ, Shen M, Kebebew E.

Endocr Relat Cancer · research support, n.i.h., intramural; research-article; journal article · DOI 10.1530/erc-12-0403

Bibliografisk träff 2013-05-09

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.

Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ.

Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(13)70152-9

Bibliografisk träff 2013-04-25

Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.

Xue SL, Cui HX, Zou JY, Xue MX, Tang XW, Zhang YM, Wu DP.

Hematol Oncol · research support, non-u.s. gov't; journal article · DOI 10.1002/hon.2051

Bibliografisk träff 2013-04-18

Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.

Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J.

Ann Hematol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1007/s00277-013-1758-5

Bibliografisk träff 2013-04-18

Doxorubicin enhances nucleosome turnover around promoters.

Yang F, Kemp CJ, Henikoff S.

Curr Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cub.2013.03.043

Bibliografisk träff 2013-04-17

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0061939

Bibliografisk träff 2013-04-02

Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.

Zhu HH, Jiang H, Jiang B, Lu J, Jiang Q, Bao L, Zhang XH, Qin YZ, Huang XJ.

Leuk Lymphoma · research support, non-u.s. gov't; journal article · DOI 10.3109/10428194.2013.776679

Bibliografisk träff 2013-03-26

Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.

Zhang X, Li Y, Zhang Y, Chen X, Zhang C, Gao L, Kong P, Liu Y, Wen Q, Zeng Y, Wang Q, Su Y, Wang C, Wang S, Yuan Z, Gao L.

Leuk Res · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.leukres.2013.03.005

Bibliografisk träff 2013-02-01

GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities.

Yang XC, Qian SJ, Wang L, Liao SD, Cao J, Hu YZ, He QJ, Zhu H, Yang B.

Transl Oncol · research-article; journal article · DOI 10.1593/tlo.12343

Bibliografisk träff 2012-04-01

Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.

Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, Nakajima A, Sakai T, Miki M, Fujita Y, Tanaka M, Kawanami T, Masaki Y, Okazaki T, Umehara H.

Anticancer Res · journal article

Bibliografisk träff 2012-01-01

[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].

Takahashi W, Nakamura Y, Tadokoro J, Handa T, Arai H, Tokita K, Iso H, Tsurumi S, Sasaki K, Maki K, Mitani K.

Rinsho Ketsueki · clinical trial; journal article

Bibliografisk träff 2011-12-13

Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.

Horinaka M, Yoshida T, Nakata S, Shiraishi T, Tomosugi M, Yoshikawa S, Wakada M, Sakai T.

Cancer Sci · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1349-7006.2011.02150.x

Bibliografisk träff 2011-11-14

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.

Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D.

J Hematol Oncol · meta-analysis; research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1186/1756-8722-4-46

Bibliografisk träff 2011-09-22

In vitro antifungal activity of DNA topoisomerase inhibitors.

Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S.

Med Mycol · journal article · DOI 10.3109/13693786.2011.609186

Bibliografisk träff 2010-12-03

Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).

Wang Y, Li W, Chen S, Qiu H, Sun A, Wu D.

Leuk Res · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2010.11.003

Bibliografisk träff 2010-09-20

Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.

Li Y, Luan Y, Qi X, Li M, Gong L, Xue X, Wu X, Wu Y, Chen M, Xing G, Yao J, Ren J.

Toxicol Sci · research support, non-u.s. gov't; journal article · DOI 10.1093/toxsci/kfq282

Bibliografisk träff 2010-04-24

Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.

Rogalska A, Szwed M, Jóźwiak Z.

Mutat Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.mrgentox.2010.04.013

Bibliografisk träff 2010-02-01

In vitro effect of DNA topoisomerase inhibitors on Candida albicans.

Kwok SC, Schelenz S, Wang X, Steverding D.

Med Mycol · research support, non-u.s. gov't; journal article · DOI 10.3109/13693780903114934

Bibliografisk träff 2010-01-05

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.

Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R.

Int J Hematol · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s12185-009-0473-4

Bibliografisk träff 2009-09-09

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.

Suzushima H, Wada N, Yamasaki H, Eto K, Shimomura T, Kugimiya MH, Horikawa K, Nishimura S, Tsuda H, Mitsuya H, Asou N.

Leuk Res · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2009.08.010